/HSIC
HSIC Stock - Henry Schein, Inc.
Healthcare|Medical - DistributionNASDAQ
$77.35+0.43%
+$0.33 (+0.43%) • Dec 19
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.82
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.84
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+9.9%upside
Target: $85.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HSIC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$76.58 – $78.12
TARGET (TP)$85.00
STOP LOSS$71.16
RISK/REWARD1:1.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.89
52W High$82.49
52W Low$60.56
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $12.67B | $12.34B | $12.65B | $12.40B | $10.12B |
| Gross Profit | $3.77B | $3.65B | $3.65B | $3.67B | $2.81B |
| Gross Margin | 29.7% | 29.6% | 28.9% | 29.6% | 27.8% |
| Operating Income | $729.00M | $714.00M | $938.00M | $854.81M | $567.40M |
| Net Income | $390.00M | $416.00M | $538.00M | $623.91M | $402.22M |
| Net Margin | 3.1% | 3.4% | 4.3% | 5.0% | 4.0% |
| EPS | $3.07 | $3.18 | $3.95 | $4.51 | $2.82 |
Company Overview
Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
42%
Hold / Neutral
7
58%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
5 Bullish7 Neutral/Bearish
Price Targets
$82
Average Target
↑ 6.0% Upside
Now
$70
Low
$82
Average
$100
High
Based on 15 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Barclays | Initiation | Overweight | $86 |
| August 26th 2025 | Evercore ISI | Upgrade | Outperform | $83 |
| July 25th 2025 | Stifel | Downgrade | Hold | $75 |
| July 14th 2025 | Robert W. Baird | Downgrade | Neutral | $72 |
| February 14th 2025 | Wells Fargo | Initiation | Equal Weight | $80 |
| January 6th 2025 | BofA Securities | Upgrade | Buy | $84← $69 |
| December 4th 2024 | Mizuho | Initiation | Neutral | $75 |
| July 22nd 2024 | Robert W. Baird | Upgrade | Outperform | $92← $81 |
| February 26th 2024 | Leerink Partners | Initiation | Market Perform | $78 |
| December 12th 2023 | JP Morgan | Upgrade | Overweight | $82← $71 |
| November 10th 2023 | Stifel | Upgrade | Buy | $70 |
| August 8th 2022 | UBS | Upgrade | Neutral | $80 |
| July 21st 2022 | Goldman | Downgrade | Neutral | $85← $93 |
| June 14th 2022 | Robert W. Baird | Downgrade | Neutral | $88← $103 |
| May 13th 2022 | Credit Suisse | Resumed | Outperform | $100 |
Earnings History & Surprises
HSICBeat Rate
56%
Last 18 quarters
Avg Surprise
+3.5%
EPS vs Estimate
Beats / Misses
10/5
3 met exactly
Latest EPS
$1.38
Q4 2025
EPS Surprise History
Q1 24
-5.7%
$0.66vs$0.70
Q2 24
+7.8%
$1.10vs$1.02
Q3 24
+0.8%
$1.23vs$1.22
Q4 24
+5.2%
$1.22vs$1.16
Q1 25
-3.3%
$1.19vs$1.23
Q2 25
+3.6%
$1.15vs$1.11
Q3 25
-6.8%
$1.10vs$1.18
Q4 25
+8.7%
$1.38vs$1.27
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 24, 2026 | $1.30 | — | — | — |
Q4 2025 | Nov 4, 2025 | $1.27 | $1.38 | +8.7% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $1.18 | $1.10 | -6.8% | ✗ MISS |
Q2 2025 | May 5, 2025 | $1.11 | $1.15 | +3.6% | ✓ BEAT |
Q1 2025 | Feb 25, 2025 | $1.23 | $1.19 | -3.3% | ✗ MISS |
Q4 2024 | Nov 5, 2024 | $1.16 | $1.22 | +5.2% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $1.22 | $1.23 | +0.8% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $1.02 | $1.10 | +7.8% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $0.70 | $0.66 | -5.7% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $1.32 | $1.32 | 0.0% | = MET |
Q3 2023 | Aug 7, 2023 | $1.28 | $1.31 | +2.3% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $1.24 | $1.21 | -2.4% | ✗ MISS |
Q1 2023 | Feb 16, 2023 | $1.21 | $1.21 | 0.0% | = MET |
Q4 2022 | Nov 1, 2022 | $1.14 | $1.09 | -4.4% | ✗ MISS |
Q3 2022 | Aug 2, 2022 | $1.16 | $1.16 | 0.0% | = MET |
Q2 2022 | May 3, 2022 | $1.19 | $1.30 | +9.2% | ✓ BEAT |
Q1 2022 | Feb 15, 2022 | $0.91 | $1.07 | +17.6% | ✓ BEAT |
Q4 2021 | Nov 2, 2021 | $0.95 | $1.10 | +15.8% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $0.97 | $1.11 | +14.4% | ✓ BEAT |
Latest News
Barclays Initiates Coverage On Henry Schein with Overweight Rating, Announces Price Target of $86
📈 PositiveBenzinga•Dec 9, 2025, 03:57 PM•Also:
Biomerica Highlights Clinical Trial Showing inFoods IBS Test Significantly Reduces Symptoms Through Guided Dietary Therapy In The Fall 2025 Issue Of Biotherapeutics Quarterly, A Henry Schein Publication
📈 PositiveBenzinga•Nov 25, 2025, 01:22 PM•Also:
JP Morgan Maintains Overweight on Henry Schein, Raises Price Target to $78
📈 PositiveBenzinga•Nov 5, 2025, 07:35 PM
Barrington Research Maintains Outperform on Henry Schein, Raises Price Target to $79
📈 PositiveBenzinga•Nov 5, 2025, 06:46 PM
Morgan Stanley Maintains Underweight on Henry Schein, Raises Price Target to $58
➖ NeutralBenzinga•Nov 5, 2025, 06:09 PM
Wells Fargo Maintains Equal-Weight on Henry Schein, Raises Price Target to $76
📈 PositiveBenzinga•Nov 5, 2025, 03:13 PM
Evercore ISI Group Maintains Outperform on Henry Schein, Raises Price Target to $90
📈 PositiveBenzinga•Nov 5, 2025, 02:12 PM
Henry Schein rises after lifting 2025 guidance
📈 PositiveSeeking Alpha•Nov 4, 2025, 02:45 PM
Henry Schein shares are trading higher after the company reported Q3 results that beat estimates and raised its full-year EPS and sales guidance.
📈 PositiveBenzinga•Nov 4, 2025, 11:08 AM
Henry Schein Approved An Amendment To Strategic Partnership Agreement Giving KKR The Right To Increase Its Ownership In HSIC Stock Up To 19.9% Through Purchases In The Open Market
📈 PositiveBenzinga•Nov 4, 2025, 11:06 AM•Also:
Henry Schein Raises FY2025 Adj EPS Guidance from $4.80-$4.94 to $4.88-$4.96 vs $4.82 Est; Raises FY2025 Sales Guidance from $12.425B-$13.180B to $13.053B-$13.180B vs $12.996B Est
📈 PositiveBenzinga•Nov 4, 2025, 11:02 AM
Henry Schein Q3 2025 Adj. EPS $1.38 Beats $1.28 Estimate, Sales $3.339B Beat $3.276B Estimate
📈 PositiveBenzinga•Nov 4, 2025, 11:00 AM
Henry Schein One Partners With Amazon Web Services To Integrate AWS's GenAI Technologies Across Henry Schein One Platform
📈 PositiveBenzinga•Nov 3, 2025, 11:34 AM•Also:
Barrington Research Maintains Outperform on Henry Schein, Maintains $78 Price Target
📈 PositiveBenzinga•Oct 22, 2025, 12:16 PM
Biomerica Enters Marketing Partnership With Henry Schein To Promote Biomerica's Infoods Irritable Bowel Syndrome Test Across The United States, Excluding New York State
📈 PositiveBenzinga•Oct 16, 2025, 12:22 PM•Also:
Biomerica Partners With Henry Schein To Market Non-Drug IBS Test Nationwide
📈 PositiveBenzinga•Oct 16, 2025, 12:21 PM•Also:
Barrington Research Maintains Outperform on Henry Schein, Maintains $78 Price Target
📈 PositiveBenzinga•Sep 23, 2025, 03:10 PM
Henry Schein Authorizes $750M Share Repurchase Plan
📈 PositiveBenzinga•Sep 9, 2025, 09:13 PM
Evercore ISI Group Upgrades Henry Schein to Outperform, Announces $83 Price Target
📈 PositiveBenzinga•Aug 26, 2025, 11:21 AM
Frequently Asked Questions about HSIC
What is HSIC's current stock price?
Henry Schein, Inc. (HSIC) is currently trading at $77.35 per share. The stock has moved +0.43% today.
What is the analyst price target for HSIC?
The average analyst price target for HSIC is $85.00, based on 1 analyst.
What sector is Henry Schein, Inc. in?
Henry Schein, Inc. operates in the Healthcare sector, specifically within the Medical - Distribution industry. The company is traded on the NASDAQ exchange.
What is HSIC's market cap?
Henry Schein, Inc. has a market capitalization of $9.48 billion, making it a mid-cap company.
Does HSIC pay dividends?
No, Henry Schein, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATR
AptarGroup, Inc.
$121.39
Mkt Cap: $8.0B
AVTR
Avantor, Inc.
$11.27
Mkt Cap: $7.7B
BIO
Bio-Rad Laboratories, Inc.
$301.53
Mkt Cap: $8.1B
DVA
DaVita Inc.
$115.20
Mkt Cap: $8.1B
GMED
Globus Medical, Inc.
$87.06
Mkt Cap: $11.7B
GRFS
Grifols, S.A.
$9.02
Mkt Cap: $7.6B
HALO
Halozyme Therapeutics, Inc.
$67.35
Mkt Cap: $7.9B
MASI
Masimo Corporation
$134.04
Mkt Cap: $7.2B
MOH
Molina Healthcare, Inc.
$163.69
Mkt Cap: $8.9B
Explore stocks similar to HSIC for comparison